Hi, I'm Dan Premack and welcome to Axios Recap, brought to you by the American Beverage Association.

Today is Monday, November 9th. Joe Biden is coming in, Donald Trump is heading out, eventually,

and we're focused on Pfizer's big vaccine news.

Earlier this morning, Pfizer and Germany's Bioentech announced that their phase 3 coronavirus

vaccine candidate showed more than 90% efficacy.

It also said it could have 50 million doses available by the end of this year and 1.3

billion doses in 2021. Three things to know. First, the FDA had set an

efficacy threshold of 50%, which means that Pfizer's candidate overperformed and then some.

Two, Pfizer didn't take any U.S. government money for development. It did, though, sign a multi-billion

dollar production and distribution

deal, which goes into effect if the vaccine receives FDA approval, and at that point, Pfizer

says the vaccine would be free of charge in the U.S. Three, we're still waiting for the vaccine

safety data, which is expected to come later this month. The bottom line here is that this is the

most promising public health news of 2020 and could help set the stage for a reopening of

schools, businesses, and overall society. In 15 seconds, we'll go deeper with Pfizer CEO Albert Borla.

But first, this.

We're joined now by Dr. Albert Borla, the CEO of Pfizer.

So Dr. Borla, can we just start with timeline here?

The company today releases these efficacy results.

When should we get kind of the other shoe to drop, which is safety?

I think the safety data will mature next week, the third week of November, as you have said.

It's already pre-scented the day because we want the median, two months from the median,

...